Patients characteristics. The characteristics of the HUS study group at baseline are presented in Table A2. The sample included only women, who on average had undergone surgery approximately 33 weeks (mean value) prior to participating in the study (Xxxxxx et al. 2012), whereas last chemotherapy cycle and radiotherapy session took place approximately 11.6 and 4 weeks (mean values) respectively, prior study participation (Xxxxxx et al. 2012). The proportion of missing values varies over time (Table A1). The response rate to the questionnaires (i.e. the percentage of patients have data at a specific time point) at month 3, month 6, month 12, month 18, month 24, month 30, month 36 and follow-up is approximately 72%, 85%, 88%, 79%, 80%, 76%, 82% and 100% respectively. It is noted that even though the overall response rate is high, there are many missing values among responders at a given time point. Characteristically there is no complete case, i.e. a patient with all variables available at all time points. The number of complete cases depends on the selected variables for univariate or multivariate analysis (either statistical or machine-learning). or Correlation Hypotheses 777167 D4.1 Preliminary Fact Grant Agreement no. TABLE A2 Patient clinical and demographic characteristics at baseline Variables Counts/ Mean(range) %/SD Variables Counts % General and Demographics Breast cancer and Treatment data Age 52.5 (35-68) 7.6 Estrogen receptor Years of education 13.9 (7-27) 3.4 Positive 443 82.0% Births 1.8 (0-6) 1 Negative 97 18.0% Exercise group Progesterone receptor No 271 47.3% Positive 362 67.0% Yes 302 52.7% Negative 178 33.0% Marital status pT Married or cohabitation 320 66.5% T1 291 53.9% Divorced 79 16.4% T2 208 38.5% Not married 62 12.9% T3 32 5.9% Widow 19 4.0% T4 7 1.3% Other 1 0.2% Tis 1 0.2% Type of work Tx 1 0.2% Agricultural 2 0.4% pN Factory, mine, construction 9 1.9% N1 205 38.0% Office, service 322 69.4% N0 178 33.0% Study or school 4 0.9% N2 64 11.9% Housewife 17 3.7% N1mi 51 9.4% Retired 76 16.4% N3 25 4.6% Unemployed 12 2.6% N0i+ 17 3.1% Other 22 4.7% Grade Menopause status before adjuvant therapy G2 242 44.8% Postmenopausal 284 52.6% G3 214 39.6% Premenopausal 256 47.4% G1 79 14.6% GX 5 0.9% Breast surgery, final Mastectomy 278 51.5% Breast-conserving 261 48.3% Axillary operation, final Dissection 405 75.0% Sentinel node biopsy 134 24.8% Adjuvant chemo Yes 495 91.7% No 45 8.3% Radiotherapy Yes 422 78.1% No 118 21.9% Herceptin No 527 98.9% Yes 6 1.1% ET Yes 447 82.8% ...
Patients characteristics. The characteristics of the study group at baseline are presented in Table A6. The sample included only women, who on average had been diagnosed with breast-cancer 15.51 months (SD=3.67) prior to participating in the study (Xxx-Xxxxxxxxx et al 2016). The patients had completed adjuvant therapy at least 3 months prior to study inclusion (Xxx-Xxxxxxxxx et al 2016).The provided cohort includes records from 201 Jewish female women after breast cancer between the ages of 26-72 (Mean= 50.45, SD=10.85), out of which 143 were born in Israel. Stages of breast cancer: Stage I (24%) Stage II (56%), D4.1 Preliminary Fact Grant Agreement no. Stage III (N= 19%). Most of the patients received both chemotherapy and radiation treatment whereas the others received exclusively chemotherapy. TABLE A6 Patient clinical and demographic characteristics at baseline Variables Count/ Mean(range) %/SD Variables Count % General and Demographics Breast cancer and Treatment data Age 50.5 (26-72) 10.9 Disease stage Births 2.7 (0-10) 1.4 1 47 24.6% Workshop participation 2 107 56.0% No 106 53.5% 3 37 19.4% Yes 92 46.5% Treatment type Married Chemo only 20 10.2% No 32 16.2% Chemo + Radio 177 89.8% Yes 166 83.8% Herceptin Children No 137 69.2% No 12 6.1% Yes 61 30.8% Yes 187 93.9% Hormonal Work status No 50 26.3% Not employed 78 41.3% Yes 140 73.7% Part time 30 15.9% Family history Full time 81 42.9% No 121 64.0% Born in Israel Yes 68 36.0% No 55 27.8% Yes 143 72.2% Urban residence No 44 22.2% Yes 154 77.8% Religious Religious 27 13.7% Traditional 49 24.9% Secular 121 61.4% The proportion of missing values varies significantly over time (Table A5). Only 20 patients have records at least some records all time points. The response rate to the questionnaires at baseline, month 3, month 6, month 12, month 24 and follow-up were approximately 99%, 24%, 55%, 43%, 26% and 69% respectively. It is noted that at month 3 the vast majority of the records comes from patients that participated in the intervention workshop (45 out of the 48 patients with records at T2).
Patients characteristics. The characteristics of the study group at baseline are presented in Table 10. The provided cohort includes records of women diagnosed with breast cancer between the ages of 28-75 (mean= 51). Stages of breast cancer: Stage I (33.3%) Stage II (51.4%), Stage III (N= 15.3%). 77% of patients had conservative breast cancer surgery, which has a positive impact in QoL, but, on the other hand, the majority have received chemotherapy (64%), which has a negative impact in QoL. Chemotherapy was mostly administered in the neoadjuvant setting (41.67%). The majority of women received radiotherapy (84.39%). Psychological assessment took place on average 16.44 months (range: 7 days- 61 months, SD=15.96 months) after diagnosis. D4.1 Preliminary Fact Grant Agreement no. TABLE 10 Patient clinical and demographic characteristics at baseline Counts Variables Mean(range)/ SD / % Variables Counts % General and Demographics Breast cancer and Treatment data Age 51.0 (28-75) 10.6 Grade Years of education 15.5 (4-24) 3.3 Grade 1 16 14.41% Marital status Grade 2 54 48.65% Married 73 68.22% Grade 3 15 13.51% Single 10 9.35% Undetermined 26 23.42% Common-law partner 5 4.67% Breast surgery Divorced 14 13.08% Lumpectomy 86 77.48% Widow 5 4.67% Mastectomy 25 22.52% Family history Axillary management None 49 44.14% SLNB 69 62.16% Breast and/or ovarian cancer 43 38.74% ALND 35 31.53% Other than breast & ovarian 19 17.12% ALND after SLNB 7 6.31% Chemotherapy Breast cancer and Treatment data Adjuvant 24 22.22% Estrogen receptor Neoadjuvant 45 41.67% Negative 14 12.61% None 39 36.11% Positive 74 66.67% Radiotherapy Undetermined 23 20.72% None 17 15.32% Progesterone receptor Local 53 47.45% Negative 19 17.12% Local-regional 41 36.94% Positive 69 62.16% Systemic treatment Undetermined 23 20.72% Chemo only 15 13.51% HER- 2 receptor Chemo plus biologicals 8 7.21% Negative 74 66.67% Chemo plus biologicals & 17 15.32% Positive 14 12.61% Chemo plus ET 32 28.83% Undetermined 23 20.72% ET only 38 34.23% Staging results - AJCC 7th Ed. Biologicals only 1 0.90% Ia 35 31.53% Ib 2 1.80% IIa 34 30.63% IIb 23 20.72% IIIa 9 8.11% IIIb 4 3.60% IIIc 4 3.60% ET ET:endocrine therapy, SLNB: Sentinel lymph node biopsy, ALND: Axillary lymph node dissection
